Cost‐effectiveness of recombinant factor VIII Fc versus emicizumab for prophylaxis in adults and adolescents with haemophilia A without inhibitors in the UK

INTRODUCTION: The economic and clinical burden of haemophilia A is high. Primary prophylaxis with factor VIII replacement therapy is the recognised standard of care, but the emergence of non‐factor therapies, such as emicizumab, is extending treatment options for people with haemophilia A. AIM: Ther...

Descripción completa

Detalles Bibliográficos
Autores principales: Kragh, Nana, Tytula, Anna, Pochopien, Michał, Aballéa, Samuel, Toumi, Mondher, Hakimi, Zalmai, Nazir, Jameel, Bystrická, Linda, Fatoye, Francis
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10107896/
https://www.ncbi.nlm.nih.gov/pubmed/36398467
http://dx.doi.org/10.1111/ejh.13901

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10107896/
https://www.ncbi.nlm.nih.gov/pubmed/36398467
http://dx.doi.org/10.1111/ejh.13901

Ejemplares similares